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Background:  Guidelines recommend that patients (pts) undergoing bioprosthetic aortic valve replacement (AVR) receive at least 3 months 
of anticoagulation with warfarin because it is believed to reduce thromboembolic events. We sought to determine the risk of events in such 
pts treated and not treated with warfarin.
methods:  We performed a retrospective analysis of pts who had undergone bioprosthetic AVR, with or without CABG, throughout the 
Geisinger Health System between 1/1/2004-4/5/2012; pts also undergoing surgery on other valves were excluded. We also excluded pts 
with a history of atrial fibrillation (AF), mitral stenosis, deep venous thrombosis (DVT), pulmonary embolus (PE), intracranial hemorrhage, 
and prior use of warfarin. Pts who developed post-op AF were also excluded. At the time of discharge a median 5 days after surgery 
(interquartile range 4-8), 322 pts met the inclusion criteria and were analyzed; 45 (14%) were discharged on warfarin, and 277 (86%) were 
not, by physician preference. Ninety-day outcome data were available for all pts.
results:  Mean age of pts not discharged on warfarin was 48+2.5 years; 65% were male, 100% were white; 42% were smokers, 17% had 
heart failure; 29% had diabetes; 2.5% were on dialysis. Mean ejection fraction was 56%. There were 2 (0.7%) deaths in the 90 days after 
discharge; 1 fatal PE, and 1 cardiac arrest of uncertain etiology. The frequency of readmission was 15% and included pericardial/pleural 
effusion (2.9%), GI bleed (2.5%), other bleed (0.7%), intra-cardiac thrombus (0.4%), DVT (0.4%), PE (0.7%, 1 of which was fatal), and 
TIA (1.1%). No pt suffered a clinically apparent MI, hemorrhagic or ischemic stroke in the 90 days after discharge. Among 45 pts (14%) 
discharged on warfarin, 2 died (4.4%), due to a ruptured aortic aneurysm on day 61, and 1 post-op arrest with MI on day 17. The frequency 
for readmission was 33% and included 2 GI bleeds (days 22 and 78), 2 large pleural effusions (days 21 and 42), and 1 DVT/PE (day 18).
conclusion:  Pts undergoing surgical AVR with a bioprosthesis who are not anticoagulated have a low risk of thrombotic complications 
(2.2%, 6 of 277 in this study; 1 DVT, 2 PEs, 3 TIAs) in the 90 days after discharge, without MIs or strokes.
